CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.

A live webcast of the event will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:

Susan Kim
+1-617-307-7503
[email protected]

Media Contact:

Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
[email protected]

 



iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales


Significant Percentage


of Licenses


Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and


Fuji


ProFound AI


for DBT Offers


Superior


Clinical


Performance


When Compared to Other Commercially Available Breast AI Systems

NASHUA, N.H., Nov. 24, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported that over 1,000 licenses have been sold as part of ProFound AI® sales since the products were launched, signaling the rapid and wide-spread adoption of the pioneering cancer detection software solution built on artificial intelligence (AI). The sales have been distributed across all major mammography system vendors and enterprise-wide viewing applications with a significant percentage to date sold to hospitals and imaging centers with GE and Siemens, as well as facilities with more than one imaging system vendor, including Hologic and Fuji.

The solid momentum is led by the Company’s growing customer base and demand for its expanded suite of leading breast health AI solutions, including ProFound AI for both Digital Breast Tomosynthesis (DBT) and 2D mammography, and interest in the recently introduced ProFound AI Risk, which is helping to transform breast cancer screening from age-based screening to risk-adapted precision screening, individualized for each woman.

“iCAD offers the full continuum of breast health AI products—both for the detection of current breast cancers and for future risk assessment,” said Michael Klein, Chairman and CEO of iCAD. “We do so on a non-exclusive, open architecture basis, therefore allowing all global customers access to the best of breed AI software available. Of significant note is that no other breast AI solution has been shown to improve radiologists’ clinical performance when reading DBT more so than ProFound AI. Specifically, our high-performing cancer detection and workflow solution offers the highest cancer detection rate, the lowest false positive rate and a dramatic 52.7% reduction in radiologists’ reading time, representing a high level of clinical significance and advantage.”

According to Kathy Schilling, MD, Medical Director of the Christine E. Lynn Women’s Health & Wellness Institute at the Boca Raton Regional Hospital, “ProFound AI for DBT rapidly and accurately analyze patients’ DBT mammography images, identifying suspicious lesions and producing quantifiable AI scores, which enables us to identify cancers earlier. The software also improves workflow issues, as we’re able to more quickly navigate through DBT datasets.”

ProFound AI Risk is the first and only commercially available clinical decision support tool to provide an accurate two-year breast cancer risk estimation based solely on a screening mammogram. Compelling research published in the peer-reviewed journal, Radiology concluded that the ProFound AI Risk model is effective at identifying women at high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.

“I was very enthusiastic about the launch of ProFound AI Risk, which I believe is more accurate than the other risk tools I’ve used, and it is very easy to integrate into my daily workflow,” said Carine Van De Merckt, MD, Radiologist at Institut Jules Bordet in Brussels, Belgium. “Furthermore, it has proven to help me in my clinical decision making, allowing me to continue to provide the best care to my patients with even more confidence.”

As part of the Company’s growth, iCAD has recently achieved significant milestones, including:

  • Sequential Revenue Growth of 44% in Third Quarter: The Company realized significant revenue growth over the second quarter in 2020, particularly with its innovative ProFound AI product offerings, which grew 44%.
  • Strong International Growth: The Company, with products now distributed in 22 countries outside the U.S., recently signed distribution agreements in Switzerland and Portugal. The first ProFound AI for DBT sold in the United Kingdom and the first ProFound AI Risk sold in Belgium both occurred in October 2020.
  • Distribution Agreement with Change Healthcare: A new agreement with the leading independent healthcare technology company, Change Healthcare, enhances commercial access to enterprise imaging and integrated delivery system networks throughout the U.S.

According to Change Healthcare’s Tracy Byers, Senior Vice President and General Manager of Imaging, as Change Healthcare looks to accelerate and transform enterprise imaging with the use of AI and cloud-native solutions, the partnership with iCAD enables them to offer their customers the ProFound AI platform as part of their Mammography Plus offering. “We are focused on radiologist productivity and aiding them with decision support tools that are elegantly integrated into their workflow,” said Byers. “The integration of iCAD’s AI solutions into our digital mammography platform will help improve patient outcomes by improving early cancer detection and enhancing clinical workflow. We could not be more excited about empowering our customers and our new partnership with iCAD.”

“iCAD’s momentum underscores the increasing demand for our comprehensive breast health AI solutions for DBT, breast density, and 2D mammography, offering clinicians a broad range of powerful tools for early disease detection and optimized reading workflow that results in improved patient outcomes,” said Stacey Stevens, president at iCAD. “This, coupled with ProFound AI’s seamless integration with major PACS for decision support capabilities across large networks, and ProFound AI’s compatibility with all leading mammography systems, allows hospitals and imaging centers with one or multi-vendor imaging systems to have a proven, standardized AI solution.

“Moreover, our principal approach to transforming breast cancer detection and care is best illustrated by our panoramic vision—to provide a more holistic view of each patient’s current imaging exam, history, and short-term risk,” continued Stevens. “With the addition of ProFound AI Risk, we intend to move mammography from primarily an age-based screening paradigm to a risk-adjusted precision screening paradigm that is truly personalized for every woman.”

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists’ reading time by 52.7%, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets. Additionally, the platform improved radiologists’ performance measured by Area Under the Curve (AUC) by nearly 6% and reduced unnecessary patient recall rates by more than 7%.i

ProFound AI Risk is currently available on an introductory basis for 2D mammography and will subsequently be available for the rapidly growing 3D mammography market.

For more information, visit www.icadmed.com and www.xoftinc.com

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians,  the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights,  product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Media Inquiries:

Amy Cook, iCAD
+1 (925) 200-2125
[email protected]

Investor Relations:

Jeremy Feffer, LifeSci Advisors
+1 (212) 915-2568
[email protected]

__________________________

i Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096



Analog Devices Reports Fourth Quarter Results Above the High-End of Outlook

Analog Devices Reports Fourth Quarter Results Above the High-End of Outlook

  • Revenue of $1.53 billion for the fourth quarter and $5.60 billion for fiscal 2020
  • B2B revenue for the fourth quarter increased 4% sequentially and 10% year-over-year
  • Operating cash flow of $2.0 billion and free cash flow of $1.8 billion for fiscal 2020
  • Returned over $1.1 billion to shareholders in fiscal 2020 and recently reinstated our buyback program

WILMINGTON, Mass.–(BUSINESS WIRE)–
Analog Devices, Inc. (Nasdaq: ADI), a leading global high-performance semiconductor company, today announced financial results for its fourth quarter and full year fiscal 2020, which ended October 31, 2020.

“ADI delivered fourth quarter results above the high-end of our outlook. We grew revenue across all of our B2B markets, expanded operating margins and increased EPS by double-digits year-over-year,” said Vincent Roche, President and CEO of Analog Devices. “Fiscal 2020 represented a year of strategic progress against an unprecedented backdrop, and our results continue to highlight the insatiable demand for our high-performance analog and mixed signal solutions. Overall, I’m proud of how our global team embraced and learned from this challenging time and continued to execute at a high level to generate and capture value for all stakeholders.”

Roche continued, “Looking ahead, our pending acquisition of Maxim Integrated is an opportunity to increase our scale and scope to deliver disruptive innovation for our customers while driving further profitable growth. The combination strengthens our industry leadership position, further diversifying our business across markets and applications and solidifying ADI as the destination for the world’s best analog talent. While the macroenvironment remains fluid, we are cautiously optimistic that a broad-based recovery is underway and expect to build on this momentum in fiscal 2021.”

Performance for the Fourth Quarter of Fiscal 2020

Results Summary(1)

 

 

 

 

 

(in millions, except per-share amounts and percentages)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Change

Revenue

$

1,526

 

 

$

1,443

 

 

6

%

Gross margin

$

1,023

 

 

$

942

 

 

9

%

Gross margin percentage

67.0

%

 

65.3

%

(2)

 

170 bps

Operating income

$

462

 

 

$

338

 

 

36

%

Operating margin

30.2

%

 

23.4

%

 

680 bps

Diluted earnings per share

$

1.04

 

 

$

0.74

 

 

41

%

 

 

 

 

 

 

Adjusted Results

 

 

 

 

 

Adjusted gross margin

$

1,068

 

 

$

987

 

 

8

%

Adjusted gross margin percentage

70.0

%

 

68.4

%

(2)

 

160 bps

Adjusted operating income

$

636

 

 

$

560

 

 

14

%

Adjusted operating margin

41.7

%

 

38.8

%

 

290 bps

Adjusted diluted earnings per share

$

1.44

 

 

$

1.19

 

 

21

%

 

 

 

 

 

 

 

 

 

Three Months

Ended

 

Trailing Twelve

Months

Cash Generation

 

 

Oct 31, 2020

 

Oct 31, 2020

Net cash provided by operating activities

 

 

$

673

 

 

$

2,008

 

% of revenue

 

 

44.1

%

 

35.8

%

Capital expenditures

 

 

$

(30)

 

 

$

(166)

 

Free cash flow

 

 

$

643

 

 

$

1,843

 

% of revenue

 

 

42.1

%

 

32.9

%

 

 

 

 

 

 

 

 

 

Three Months

Ended

 

Trailing Twelve

Months

Cash Return

 

 

Oct 31, 2020

 

Oct 31, 2020

Dividend paid

 

 

$

(230)

 

 

$

(886)

 

Stock repurchases

 

 

(7)

 

 

(244)

 

Total cash returned

 

 

$

(237)

 

 

$

(1,131)

 

(1) The sum and/or computation of the individual amounts may not equal the total due to rounding.

(2) Includes approximately 140 basis points of impact from a write-down of inventory associated with a customer within our Communications end market.

Outlook for the First Quarter of Fiscal Year 2021

For the first quarter of fiscal 2021, we are forecasting revenue of $1.50 billion, +/- $70 million. At the midpoint of this revenue outlook, we expect reported operating margin of approximately 29.1%, +/- 150 bps, and adjusted operating margin of approximately 40.0%, +/- 100 bps. We are planning for reported EPS to be $0.92, +/- $0.10, and adjusted EPS to be $1.30, +/- $0.10.

Our first quarter fiscal 2021 outlook is based on current expectations and actual results may differ materially, as a result of, among other things, the important factors discussed at the end of this release. These statements supersede all prior statements regarding our business outlook set forth in prior ADI news releases, and ADI disclaims any obligation to update these forward-looking statements.

The adjusted results and adjusted anticipated results above are financial measures presented on a non-GAAP basis. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided in the financial tables included in this press release. See also “Non-GAAP Financial Information” section for additional information.

Dividend Payment

The ADI Board of Directors has declared a quarterly cash dividend of $0.62 per outstanding share of common stock. The dividend will be paid on December 15, 2020 to all shareholders of record at the close of business on December 4, 2020.

Conference Call Scheduled for Today, Tuesday, November 24, 2020 at 10:00 am ET

ADI will host a conference call to discuss our fourth quarter fiscal 2020 results and short-term outlook today, beginning at 10:00 am ET. Investors may join via webcast, accessible at investor.analog.com, or by telephone (call 800-859-9560, or 706-634-7193 for international calls, ten minutes before the call begins and provide the password “ADI”).

A replay will be available two hours after the completion of the call. The replay may be accessed for up to two weeks by dialing 855-859-2056 (replay only) and providing the conference ID: 5297321, or by visiting investor.analog.com.

Non-GAAP Financial Information

This release includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles (GAAP) and may be different from non-GAAP measures presented by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. These non-GAAP measures have material limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP and should not be considered in isolation from, or as a substitute for, the Company’s financial results presented in accordance with GAAP. The Company’s use of non-GAAP measures, and the underlying methodology when including or excluding certain items, is not necessarily an indication of the results of operations that may be expected in the future, or that the Company will not, in fact, record such items in future periods. You are cautioned not to place undue reliance on these non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are provided in the financial tables included in this release.

Management uses non-GAAP measures internally to evaluate the Company’s operating performance from continuing operations against past periods and to budget and allocate resources in future periods. These non-GAAP measures also assist management in evaluating the Company’s core business and trends across different reporting periods on a consistent basis. Management also uses these non-GAAP measures as the primary performance measurement when communicating with analysts and investors regarding the Company’s earnings results and outlook and believes that the presentation of these non-GAAP measures is useful to investors because it provides investors with the operating results that management uses to manage the Company and enables investors and analysts to evaluate the Company’s core business. Management also believes that the non-GAAP liquidity measure free cash flow is useful both internally and to investors because it provides information about the amount of cash generated after capital expenditures that is then available to repay debt obligations, make investments and fund acquisitions, and for certain other activities.

The non-GAAP financial measures referenced by ADI in this release include: adjusted gross margin, adjusted gross margin percentage, adjusted operating expenses, adjusted operating expenses percentage, adjusted operating income, adjusted operating margin, adjusted income before income taxes, adjusted provision for income taxes, adjusted tax rate, adjusted diluted earnings per share (EPS), free cash flow, and free cash flow margin percentage.

Adjusted gross margin is defined as gross margin, determined in accordance with GAAP, excluding certain acquisition related expenses1 which are described further below. Adjusted gross margin percentage represents adjusted gross margin divided by revenue.

Adjusted operating expenses is defined as operating expenses, determined in accordance with GAAP, excluding: certain acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; and charitable foundation contribution4which are described further below. Adjusted operating expenses percentage represents adjusted operating expenses divided by revenue.

Adjusted operating income is defined as operating income, determined in accordance with GAAP, excluding: acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; and charitable foundation contribution4 which are described further below. Adjusted operating margin represents adjusted operating income divided by revenue.

Adjusted income before income taxes is defined as income before income taxes, determined in accordance with GAAP, excluding: acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; and charitable foundation contribution4which are described further below.

Adjusted provision for income taxes is defined as provision for income taxes, determined in accordance with GAAP, excluding tax related items5 which are described further below. Adjusted tax rate represents adjusted provision for income taxes divided by adjusted income before income taxes.

Adjusted diluted EPS is defined as diluted EPS, determined in accordance with GAAP, excluding: acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; charitable foundation contribution4; and tax related items5 which are described further below.

Free cash flow is defined as net cash provided by operating activities, determined in accordance with GAAP, less additions to property, plant and equipment, net. Free cash flow margin percentage represents free cash flow divided by revenue.

1Acquisition Related Expenses: Expenses incurred as a result of current and prior period acquisitions and primarily include expenses associated with the fair value adjustments to inventory, property, plant and equipment and amortization of acquisition related intangibles, which include acquired intangibles such as purchased technology and customer relationships. Expenses also include severance payments, equity award accelerations, and the fair value adjustment associated with the replacement of share-based awards related to the Linear Technology Corporation (Linear) acquisition. We excluded these costs from our non-GAAP measures because they relate to specific transactions and are not reflective of our ongoing financial performance.

2Acquisition Related Transaction Costs: Costs directly related to the proposed Maxim Integrated Products, Inc. acquisition, including legal, accounting and other professional fees as well as integration-related costs. We excluded these costs from our non-GAAP measures because they relate to a specific transaction and are not reflective of our ongoing financial performance.

3Restructuring Related Expense: Expenses incurred in connection with facility closures, consolidation of manufacturing facilities, severance, other accelerated stock-based compensation expense and other cost reduction efforts or reorganizational initiatives. We excluded these expenses from our non-GAAP measures because apart from ongoing expense savings as a result of such items, these expenses have no direct correlation to the operation of our business in the future.

4Charitable Foundation Contribution: Expenses incurred in connection with a one time contribution of registered shares of common stock to the Analog Devices Foundation. We excluded this expense from our non-GAAP measures because this expense has no direct correlation to the operation of our business in the future.

5Tax Related Items: Income tax effect of the non-GAAP items discussed above and income tax from certain discrete tax items primarily related to the resolution of prior period tax audits, income tax from certain uncertain tax positions, income tax from state valuation allowance adjustments, income tax on certain inventory intra-entity transfers, the impact of a voluntary accounting policy change and other income tax adjustments related to prior periods. We excluded the income tax benefit / provision effect of these tax related items from our non-GAAP measures because they are not associated with the tax expense on our ongoing operating results.

About Analog Devices

Analog Devices (Nasdaq: ADI) is a leading global high-performance analog technology company dedicated to solving the toughest engineering challenges. We enable our customers to interpret the world around us by intelligently bridging the physical and digital with unmatched technologies that sense, measure, power, connect and interpret. Visit http://www.analog.com.

Forward Looking Statements

This press release contains forward-looking statements, which address a variety of subjects including, for example, our statements regarding our proposed acquisition of Maxim Integrated Products, Inc. (“Maxim”); the impact of the COVID-19 pandemic on our business, financial condition and results of operations; expected revenue, operating margin, tax rate, earnings per share, and other financial results; expected market trends, market share gains, operating leverage, production and inventory levels; expected customer demand and order rates for our products and expected product offerings; product development; and marketing position. Statements that are not historical facts, including statements about our beliefs, plans and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: the uncertainty as to the extent of the duration, scope and impacts of the COVID-19 pandemic; political and economic uncertainty, including any faltering in global economic conditions or the stability of credit and financial markets; erosion of consumer confidence and declines in customer spending; unavailability of raw materials, services, supplies or manufacturing capacity; changes in geographic, product or customer mix; changes in export classifications, import and export regulations or duties and tariffs; changes in our or Maxim’s estimates of our respective expected tax rates based on current tax law; our ability to successfully integrate Maxim’s businesses and technologies; the risk that the expected benefits and synergies of the proposed transaction and growth prospects of the combined company may not be fully achieved in a timely manner, or at all; adverse results in litigation matters, including the potential for litigation related to the proposed transaction; the risk that we or Maxim will be unable to retain and hire key personnel; the risk associated with the timing of the closing of the proposed transaction, including the risk that the conditions to the transaction are not satisfied on a timely basis or at all or the failure of the transaction to close for any other reason or to close on the anticipated terms, including the anticipated tax treatment; the risk that any regulatory approval, consent or authorization that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; unanticipated difficulties or expenditures relating to the transaction, the response of business partners and retention as a result of the announcement and pendency of the transaction; uncertainty as to the long-term value of our common stock; the diversion of management time on transaction-related matters; our ability to successfully integrate acquired businesses and technologies; and the risk that expected benefits, synergies and growth prospects of acquisitions may not be fully achieved in a timely manner, or at all. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission (“SEC”), including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Analog Devices and the Analog Devices logo are registered trademarks or trademarks of Analog Devices, Inc. All other trademarks mentioned in this document are the property of their respective owners.

ANALOG DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per share amounts)

 

 

Three Months Ended

 

Twelve Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Oct 31, 2020

 

Nov 2, 2019

Revenue

$

1,526,295

 

 

$

1,443,219

 

 

$

5,603,056

 

 

$

5,991,065

 

Cost of sales

503,211

 

 

501,028

 

 

1,912,578

 

 

1,977,315

 

Gross margin

1,023,084

 

 

942,191

 

 

3,690,478

 

 

4,013,750

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

280,239

 

 

277,018

 

 

1,050,519

 

 

1,130,348

 

Selling, marketing, general and administrative

165,115

 

 

154,799

 

 

659,923

 

 

648,094

 

Amortization of intangibles

108,007

 

 

107,225

 

 

429,455

 

 

429,041

 

Special charges

8,051

 

 

64,788

 

 

52,337

 

 

95,659

 

Total operating expenses

561,412

 

 

603,830

 

 

2,192,234

 

 

2,303,142

 

Operating income

461,672

 

 

338,361

 

 

1,498,244

 

 

1,710,608

 

Nonoperating expense (income):

 

 

 

 

 

 

 

Interest expense

48,593

 

 

50,775

 

 

193,305

 

 

229,075

 

Interest income

(527)

 

 

(1,988)

 

 

(4,305)

 

 

(10,229)

 

Other, net

(3,704)

 

 

1,747

 

 

(2,373)

 

 

6,034

 

 

44,362

 

 

50,534

 

 

186,627

 

 

224,880

 

Income before income taxes

417,310

 

 

287,827

 

 

1,311,617

 

 

1,485,728

 

Provision for income taxes

30,784

 

 

10,133

 

 

90,856

 

 

122,717

 

Net income

$

386,526

 

 

$

277,694

 

 

$

1,220,761

 

 

$

1,363,011

 

 

 

 

 

 

 

 

 

Shares used to compute earnings per share – basic

369,284

 

 

369,051

 

 

368,633

 

 

369,133

 

Shares used to compute earnings per share – diluted

372,322

 

 

372,584

 

 

371,973

 

 

372,871

 

 

 

 

 

 

 

 

 

Basic earnings per common share

$

1.05

 

 

$

0.75

 

 

$

3.31

 

 

$

3.68

 

Diluted earnings per common share

$

1.04

 

 

$

0.74

 

 

$

3.28

 

 

$

3.65

 

ANALOG DEVICES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

 

 

October 31, 2020

 

November 2, 2019

Cash & cash equivalents

$

1,055,860

 

 

$

648,322

 

Accounts receivable

737,536

 

 

635,136

 

Inventories

608,260

 

 

609,886

 

Other current assets

116,032

 

 

91,782

 

Total current assets

2,517,688

 

 

1,985,126

 

Net property, plant and equipment

1,120,561

 

 

1,219,989

 

Other investments

86,729

 

 

77,324

 

Goodwill

12,278,425

 

 

12,256,880

 

Intangible assets, net

3,650,280

 

 

4,217,224

 

Deferred tax assets

1,503,064

 

 

1,582,382

 

Other assets

311,856

 

 

53,716

 

Total assets

$

21,468,603

 

 

$

21,392,641

 

 

 

 

 

Other current liabilities

$

1,364,986

 

 

$

1,208,965

 

Debt, current

 

 

299,667

 

Long-term debt

5,145,102

 

 

5,192,252

 

Deferred income taxes

1,919,595

 

 

2,088,212

 

Other non-current liabilities

1,040,975

 

 

894,357

 

Shareholders’ equity

11,997,945

 

 

11,709,188

 

Total liabilities & equity

$

21,468,603

 

 

$

21,392,641

 

 

 

 

 

ANALOG DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

Three Months Ended

 

Twelve Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Oct 31, 2020

 

Nov 2, 2019

Cash flows from operating activities:

 

 

 

 

 

 

 

Net income

$

386,526

 

 

$

277,694

 

 

$

1,220,761

 

 

$

1,363,011

 

Adjustments to reconcile net income to net cash provided by operations:

 

 

 

 

 

 

 

Depreciation

57,053

 

 

61,636

 

 

233,775

 

 

240,677

 

Amortization of intangibles

145,163

 

 

143,528

 

 

577,148

 

 

570,574

 

Stock-based compensation expense

36,557

 

 

37,580

 

 

149,518

 

 

150,300

 

Non-cash impairment included in special charges

 

 

9,800

 

 

 

 

14,167

 

Deferred income taxes

(71,146)

 

 

(35,809)

 

 

(113,948)

 

 

(91,253)

 

Non-cash contribution to charitable foundation

 

 

 

 

40,000

 

 

 

Other non-cash activity

(257)

 

 

14,206

 

 

5,418

 

 

40,907

 

Changes in operating assets and liabilities

118,702

 

 

149,270

 

 

(104,185)

 

 

(35,283)

 

Total adjustments

286,072

 

 

380,211

 

 

787,726

 

 

890,089

 

Net cash provided by operating activities

672,598

 

 

657,905

 

 

2,008,487

 

 

2,253,100

 

Percent of revenue

44.1

%

 

45.6

%

 

35.8

%

 

37.6

%

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Additions to property, plant and equipment

(29,888)

 

 

(51,076)

 

 

(165,692)

 

 

(275,372)

 

Payments for acquisitions, net of cash acquired

(1,433)

 

 

(11,170)

 

 

(14,196)

 

 

(11,170)

 

Change in other assets

579

 

 

(1,512)

 

 

(635)

 

 

(6,644)

 

Net cash used for investing activities

(30,742)

 

 

(63,758)

 

 

(180,523)

 

 

(293,186)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Proceeds from debt

 

 

 

 

395,646

 

 

1,250,000

 

Early termination of debt

 

 

 

 

 

 

(1,250,000)

 

Proceeds from revolver

 

 

 

 

350,000

 

 

75,000

 

Payments on revolver

 

 

 

 

(350,000)

 

 

(75,000)

 

Debt repayments

(450,000)

 

 

(200,000)

 

 

(750,000)

 

 

(850,000)

 

Dividend payments to shareholders

(229,597)

 

 

(200,196)

 

 

(886,155)

 

 

(777,481)

 

Repurchase of common stock

(7,222)

 

 

(172,389)

 

 

(244,487)

 

 

(613,005)

 

Proceeds from employee stock plans

10,653

 

 

10,388

 

 

68,403

 

 

116,523

 

Change in other financing activities

 

 

5,087

 

 

(4,015)

 

 

(2,831)

 

Net cash used for financing activities

(676,166)

 

 

(557,110)

 

 

(1,420,608)

 

 

(2,126,794)

 

Effect of exchange rate changes on cash

(94)

 

 

(879)

 

 

182

 

 

(1,389)

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

(34,404)

 

 

36,158

 

 

407,538

 

 

(168,269)

 

Cash and cash equivalents at beginning of period

1,090,264

 

 

612,164

 

 

648,322

 

 

816,591

 

Cash and cash equivalents at end of period

$

1,055,860

 

 

$

648,322

 

 

$

1,055,860

 

 

$

648,322

 

 

 

 

 

 

 

 

 

ANALOG DEVICES, INC.

REVENUE TRENDS BY END MARKET

(Unaudited)

(In thousands)

The categorization of revenue by end market is determined using a variety of data points including the technical characteristics of the product, the “sold to” customer information, the “ship to” customer information and the end customer product or application into which our product will be incorporated. As data systems for capturing and tracking this data and our methodology evolves and improves, the categorization of products by end market can vary over time. When this occurs, we reclassify revenue by end market for prior periods. Such reclassifications typically do not materially change the sizing of, or the underlying trends of results within, each end market.

 

 

Three Months Ended

 

 

Oct 31, 2020

 

Nov 2, 2019

 

 

Revenue

 

% of revenue*

 

Y/Y %

 

Revenue

 

% of revenue*

Industrial

 

$

811,226

 

 

53%

 

9%

 

$

745,672

 

 

52%

Communications

 

312,649

 

 

20%

 

19%

 

262,808

 

 

18%

Automotive

 

229,781

 

 

15%

 

2%

 

226,057

 

 

16%

Consumer

 

172,639

 

 

11%

 

(17)%

 

208,682

 

 

14%

Total revenue

 

$

1,526,295

 

 

100%

 

6%

 

$

1,443,219

 

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

Twelve Months Ended

 

 

Oct 31, 2020

 

Nov 2, 2019

 

 

Revenue

 

% of revenue*

 

Y/Y %

 

Revenue

 

% of revenue*

Industrial

 

$

2,987,542

 

 

53%

 

(1)%

 

$

3,011,411

 

 

50%

Communications

 

1,195,946

 

 

21%

 

(8)%

 

1,294,960

 

 

22%

Automotive

 

779,276

 

 

14%

 

(16)%

 

930,613

 

 

16%

Consumer

 

640,292

 

 

11%

 

(15)%

 

754,081

 

 

13%

Total revenue

 

$

5,603,056

 

 

100%

 

(6)%

 

$

5,991,065

 

 

100%

 

 

 

 

 

 

 

 

 

 

 

*The sum of the individual percentages may not equal the total due to rounding.

ANALOG DEVICES, INC.

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

(Unaudited)

(In thousands, except per share amounts)

 

 

Three Months Ended

 

Twelve Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Oct 31, 2020

 

Nov 2, 2019

 

 

 

 

 

 

 

 

Gross margin

$

1,023,084

 

 

$

942,191

 

 

$

3,690,478

 

 

$

4,013,750

 

Gross margin percentage

67.0

%

 

65.3

%

 

65.9

%

 

67.0

%

Acquisition related expenses

44,741

 

 

44,822

 

 

179,374

 

 

175,266

 

Adjusted gross margin

$

1,067,825

 

 

$

987,013

 

 

$

3,869,852

 

 

$

4,189,016

 

Adjusted gross margin percentage

70.0

%

 

68.4

%

 

69.1

%

 

69.9

%

 

 

 

 

 

 

 

 

Operating expenses

$

561,412

 

 

$

603,830

 

 

$

2,192,234

 

 

$

2,303,142

 

Percent of revenue

36.8

%

 

41.8

%

 

39.1

%

 

38.4

%

Acquisition related expenses

(110,963)

 

 

(112,219)

 

 

(444,261)

 

 

(451,511)

 

Acquisition related transaction costs

(10,977)

 

 

 

 

(20,098)

 

 

 

Charitable foundation contribution

 

 

 

 

(40,000)

 

 

 

Restructuring related expense

(8,050)

 

 

(64,788)

 

 

(52,337)

 

 

(95,659)

 

Adjusted operating expenses

$

431,422

 

 

$

426,823

 

 

$

1,635,538

 

 

$

1,755,972

 

Adjusted operating expenses percentage

28.3

%

 

29.6

%

 

29.2

%

 

29.3

%

 

 

 

 

 

 

 

 

Operating income

$

461,672

 

 

$

338,361

 

 

$

1,498,244

 

 

$

1,710,608

 

Operating margin

30.2

%

 

23.4

%

 

26.7

%

 

28.6

%

Acquisition related expenses

155,704

 

 

157,041

 

 

623,635

 

 

626,777

 

Acquisition related transaction costs

10,977

 

 

 

 

20,098

 

 

 

Charitable foundation contribution

 

 

 

 

40,000

 

 

 

Restructuring related expense

8,050

 

 

64,788

 

 

52,337

 

 

95,659

 

Adjusted operating income

$

636,403

 

 

$

560,190

 

 

$

2,234,314

 

 

$

2,433,044

 

Adjusted operating margin

41.7

%

 

38.8

%

 

39.9

%

 

40.6

%

 

 

 

 

 

 

 

 

Provision for income taxes

$

30,784

 

 

$

10,133

 

 

$

90,856

 

 

$

122,717

 

Income tax effect of adjustments above

26,878

 

 

35,903

 

 

106,291

 

 

104,470

 

Income tax from certain discrete tax items

 

 

20,302

 

 

25,951

 

 

61,227

 

Adjusted provision for income taxes

$

57,662

 

 

$

66,338

 

 

$

223,098

 

 

$

288,414

 

 

 

 

 

 

 

 

 

Income before income taxes

$

417,310

 

 

$

287,827

 

 

$

1,311,617

 

 

$

1,485,728

 

Effective tax rate

7.4

%

 

3.5

%

 

6.9

%

 

8.3

%

Acquisition related expenses

155,704

 

 

157,041

 

 

623,635

 

 

626,777

 

Acquisition related transaction costs

10,977

 

 

 

 

20,098

 

 

 

Charitable foundation contribution

 

 

 

 

40,000

 

 

 

Restructuring related expense

8,050

 

 

64,788

 

 

52,337

 

 

95,659

 

Adjusted income before income taxes

$

592,041

 

 

$

509,656

 

 

$

2,047,687

 

 

$

2,208,164

 

Adjusted tax rate

9.7

%

 

13.0

%

 

10.9

%

 

13.1

%

 

 

 

 

 

 

 

 

Diluted EPS

$

1.04

 

 

$

0.74

 

 

$

3.28

 

 

$

3.65

 

Acquisition related expenses

0.42

 

 

0.42

 

 

1.68

 

 

1.68

 

Acquisition related transaction costs

0.03

 

 

 

 

0.05

 

 

 

Charitable foundation contribution

 

 

 

 

0.11

 

 

 

Restructuring related expense

0.02

 

 

0.17

 

0.14

 

 

0.26

 

Income tax effect of adjustments above

(0.07)

 

 

(0.10)

 

 

(0.29)

 

 

(0.28)

 

Income tax from certain discrete tax items

 

 

(0.05)

 

 

(0.07)

 

 

(0.16)

 

Adjusted diluted EPS*

$

1.44

 

 

$

1.19

 

 

$

4.91

 

 

$

5.15

 

* The sum of the individual per share amounts may not equal the total due to rounding.

ANALOG DEVICES, INC.

RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW

(Unaudited)

(In thousands)

 

 

Trailing

Twelve

Months

 

Three Months Ended

 

Oct 31, 2020

 

Oct 31, 2020

 

Aug 1, 2020

 

May 2, 2020

 

Feb 1, 2020

Revenue

$

5,603,056

 

 

$

1,526,295

 

 

$

1,456,136

 

 

$

1,317,060

 

 

$

1,303,565

 

Net cash provided by operating activities

$

2,008,487

 

 

$

672,598

 

 

$

557,200

 

 

$

429,041

 

 

$

349,648

 

% of Revenue

36

%

 

44

%

 

38

%

 

33

%

 

27

%

Capital expenditures

$

(165,692)

 

 

$

(29,888)

 

 

$

(20,804)

 

 

$

(60,161)

 

 

$

(54,839)

 

Free cash flow

$

1,842,795

 

 

$

642,710

 

 

$

536,396

 

 

$

368,880

 

 

$

294,809

 

% of Revenue

33

%

 

42

%

 

37

%

 

28

%

 

23

%

ANALOG DEVICES, INC.

RECONCILIATION OF PROJECTED GAAP TO NON-GAAP RESULTS

(Unaudited)

 

 

Three Months Ending January 30, 2021

 

Reported

 

Adjusted

Revenue

$1.50 Billion

 

$1.50 Billion

 

(+/- $70 Million)

 

(+/- $70 Million)

Operating margin

29.1%

 

40.0% (1)

 

(+/-150 bps)

 

(+/-100 bps)

Nonoperating expenses

~ $43 Million

 

~ $43 Million

Tax rate

12% to 14%

 

12% to 14% (2)

Earnings per share

$0.92

 

$1.30 (3)

 

(+/- $0.10)

 

(+/- $0.10)

(1) Includes $163 million of adjustments related to acquisition related expenses and acquisition related transaction costs as previously defined in the Non-GAAP Financial Information section of this press release.

(2) Includes $23 million of tax effects associated with the adjustment for acquisition related expenses and acquisition related transaction costs noted above.

(3) Includes $0.38 of adjustments related to the net impact of $0.44 of acquisition related expenses and acquisition related transaction costs, as well as $0.06 of tax effects on those items.

(ADI WEB)

Investor Contact:

Analog Devices, Inc.

Mr. Michael Lucarelli

Sr. Director of Investor Relations

781-461-3282

[email protected]

Media Contacts:

Teneo

Ms. Andrea Calise

917-826-3804

[email protected]

Teneo

Ms. Megan Fenton

917-860-0356

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Semiconductor Hardware Manufacturing Technology Engineering

MEDIA:

Logo
Logo

Harvest Capital Credit Corporation Announces Record Date and Payment Date for Previously Deferred Dividend Payments

Harvest Capital Credit Corporation Announces Record Date and Payment Date for Previously Deferred Dividend Payments

NEW YORK–(BUSINESS WIRE)–
Harvest Capital Credit Corporation (the “Company,” “we,” or “our”) (NASDAQ: HCAP) today announced that the Board of Directors has determined a record date and payment date for the Company’s previously declared but deferred March 2020 and April 2020 monthly dividends of $0.08 per share, respectively. These deferred dividends will now be payable in a single distribution of $0.16 per share on December 29, 2020 to shareholders of record at the close of business on December 15, 2020.

“We previously deferred the record and payment dates for our March 2020 and April 2020 dividends in light of the unprecedented circumstances surrounding the COVID-19 pandemic, which was part of an overall plan to preserve liquidity,” said Joseph Jolson, Chairman and CEO. “In light of the progress the Company has made paying down its bank line of credit and to avoid the imposition of a federal excise tax on the Company’s undistributed earnings, the Board of Directors believes it is in the Company’s best interests to make this dividend distribution prior to year-end,” concluded Mr. Jolson.

About Harvest Capital Credit Corporation

Harvest Capital Credit Corporation (NASDAQ: HCAP) provides customized financing solutions to privately held small and mid-sized companies in the U.S., generally targeting companies with annual revenues of less than $100 million and annual EBITDA of less than $15 million. The company’s investment objective is to generate both current income and capital appreciation primarily by making direct investments in the form of subordinated debt, senior debt and, to a lesser extent, minority equity investments. Harvest Capital Credit Corporation is externally managed and has elected to be treated as a business development company under the Investment Company Act of 1940.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, except as may be required by law.

Investor & Media Relations Contacts

Harvest Capital Credit Corporation

Joseph A. Jolson

Chairman & Chief Executive Officer

(415) 835-8970

[email protected]

William E. Alvarez, Jr.

Chief Financial Officer

(212) 906-3589

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Consulting Banking Professional Services Finance

MEDIA:

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

MARIETTA, Ohio–(BUSINESS WIRE)–
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing and interpreting the results analysing the benefit of PKX-001 on human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to an experimental model of blindness due to retina degeneration. The paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing. Given the priority of this study, the paper has been made publically available now during the review process as a pre-print for a limited time for other stakeholders and scientists to review, discuss, or comment, here: https://www.biorxiv.org/content/10.1101/2020.11.22.393439v1

Vision loss due to degeneration of the retina, most commonly the macula, commonly appears with aging, comorbid cardiovascular conditions, genetics, or other exposures. Macular degeneration currently has no cure. It is the leading cause of reduced sharp central vision necessary for such tasks as reading or driving.

Cells transplanted without PKX-001 did not show any statistical benefits in electroretinography (ERG) or optokinetic tracking (OKT) used to measure vision function. By comparison, PKX-001 treated cells showed 3-fold greater improvement in both ERG & OKT — with more transplanted cells surviving long-term in the retina. Only PKX-001 treated cells showed maturation and integration with the host retina.

“In this experimental model of retinal degeneration, iPSC derived retinal precursor cells treated with PKX-001 remarkably improved cellular integration after transplantation to secure functional vision benefits.” – Dr. Kevin Gregory-Evans M.D., Ph.D.

PKX-001 is the designation given to the lead drug product molecule of the AAGP® family.

This study was completed by Dr. Kevin Gregory-Evans, MD, PhD, Professor of Opthalmology & the Julia Levy Leadership Chair in Macular Research at the University of British Columbia. A panel member of the California Institute of Regenerative Medicine & Canadian Institutes of Health Research. Previously, a reader in molecular ophthalmology at Imperial College London. An ophthalmologist and global leader in macular research and regenerative medicine development.

Dr. Kevin Gregory-Evans on ProtoKinetix AAGP®
Dr. Gregory-Evans Bio

Global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc. According to market research published by iHealthcareAnalyst, the global market for organ transplantation is estimated to reach $51 billion by 2025, growing at a CAGR of 9.9% over the forecast period, driven by an aging population with increasing incidence of chronic disease, organ failures, and rising demand for transplant products, such as tissue products, immunosuppressants, and organ preservation solutions.

“Our molecule offers significant benefits to the field of regenerative medicine already. Seeing more scientific success of this magnitude is exciting as we seek further partnership for clinical trials. Our company mission and values are to benefit patients in need and I am confident AAGP is the stem cell helper to do just that.” – Clarence Smith, CEO President

See the promising research of AAGP® and results to date

Visit our new website at ProtoKinetix.com for more information and to join our email list.

About ProtoKinetix, Incorporated

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.

Clarence E. Smith

President and chief executive officer

Telephone: 740-434-5041
Email: [email protected]

Twitter: @ProtoKinetix

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Health Stem Cells Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Kohl’s Named to Dow Jones Sustainability Index for Third Consecutive Year

Kohl’s Named to Dow Jones Sustainability Index for Third Consecutive Year

2020 designation recognizes company’s continued commitment to sustainability efforts

MENOMONEE FALLS, Wis.–(BUSINESS WIRE)–Kohl’s (NYSE: KSS) is proud to have been named to the 2020 Dow Jones Sustainability Index (DJSI) North America by S&P Global. This marks the third year in a row the company has received the designation for its sustainability performance and environmental, social and governance (ESG) commitments.

“The DJSI’s continued recognition of Kohl’s serves as a reliable indicator of the strength of our ESG stewardship initiatives,” said Steve Thomas, Chief Risk and Compliance Officer for Kohl’s. “We believe that incorporating sustainable solutions into the way Kohl’s conducts business will help to build better futures for our customers, our associates, and their families and we are pleased to be acknowledged for these efforts.”

Launched in 1999 as one of the first global sustainability benchmarks, the DJSI measures the performance of the world’s leading companies based on financially material environmental, social, and governance factors. The DJSI helps to evaluate a company’s impact on people, communities and the planet for socially-conscious investors.

“We congratulate Kohl’s for being included in the DJSI North America. A DJSI distinction is a reflection of being a sustainability leader in your industry. With a record number of companies participating in the 2020 Corporate Sustainability Assessment and more stringent rules for inclusion this year, this sets your company apart and rewards your continued commitment to people and planet,” said Manjit Jus, Global Head of ESG Research and Data, S&P Global.

Earlier this month, Kohl’s was also recognized with a SmartWay® 2020 Excellence Award from the U.S. Environmental Protection Agency (EPA) as an industry leader in freight supply chain, environmental performance and energy efficiency. Kohl’s was one of just 17 shipper and logistics companies to receive the distinction this year, in recognition of the company’s sustainability efforts and exceptional performance moving goods in the cleanest and most energy-efficient way possible, leading to cleaner and healthier communities.

For more details about Kohl’s commitment to sustainability, please refer to the company’s 2019 CSR Report. Additional information about Kohl’s Environmental, Social, and Governance (ESG) efforts can be found on the company’s corporate website, Corporate.Kohls.com.

About Kohl’s

Kohl’s (NYSE: KSS) is a leading omnichannel retailer with more than 1,100 stores in 49 states. With a commitment to inspiring and empowering families to lead fulfilled lives, Kohl’s offers amazing national and exclusive brands, incredible savings and an easy shopping experience in our stores, online at Kohls.com and on the Kohl’s mobile app. Since its founding, Kohl’s has given more than $750 million to support communities nationwide, with a focus on family health and wellness. For a list of store locations or to shop online, visit Kohls.com. For more information about Kohl’s impact in the community or how to join our winning team, visit Corporate.Kohls.com or follow @KohlsNews on Twitter.

KSS-IR

Julia Fennelly, [email protected], 262.703.1710

 

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Other Retail Online Retail Philanthropy Discount/Variety Department Stores Specialty Consumer Catalog Environment Fashion Retail Other Philanthropy Home Goods

MEDIA:

Logo
Logo

PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice

PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice

SALT LAKE CITY–(BUSINESS WIRE)–PolarityTE, Inc. (Nasdaq: PTE), a companyfocused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the dismissal with prejudice of a consolidated class action lawsuit filed in the United States District Court for the District of Utah under the caption In re PolarityTE, Inc. Securities Litigation,Case No. 2:18-cv-00510. The Court’s order was based on the Company’s motion to dismiss filed on June 3, 2019.

Two lawsuits were brought against the Company and certain of its current and former officers and directors on June 26, 2018 and July 6, 2018 by shareholders purporting to represent a class consisting of purchasers of the Company’s common stock. The lawsuits were consolidated and an amended complaint was filed on April 2, 2019. On November 22, 2020, the Court granted the defendants’ motion to dismiss the consolidated Complaint with prejudice. By dismissing the lawsuit with prejudice, the Court has made a final determination in this matter. The plaintiff has a right to appeal the Court’s decision.

David Seaburg, Chief Executive Officer, commented, “We are pleased with the dismissal of this meritless action. We view the dismissal with prejudice as a strong repudiation of the baseless criticisms that were levied regarding our Company, its technology, and its intellectual property portfolio. We will continue to advance our patient-centric mission and to execute on the fundamentals of our business as we move forward.”

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient’s own tissue and uses the patient’s own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE’s innovative methods are intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

Investors:

Rich Haerle

VP, Investor Relations

PolarityTE, Inc.

[email protected]

(385) 315-0697

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

KB Home Announces the Grand Opening of Meadows at Scott Lake Creek, Its Latest New-Home Community in Lakeland, Florida

KB Home Announces the Grand Opening of Meadows at Scott Lake Creek, Its Latest New-Home Community in Lakeland, Florida

Homebuilder’s community offers personalized, new homes in a desirable location priced from the $240,000s.

LAKELAND, Fla.–(BUSINESS WIRE)–
KB Home (NYSE: KBH) today announced the grand opening of Meadows at Scott Lake Creek, a new single-family home community in Lakeland. Meadows at Scott Lake’s commuter-friendly location is near area employers, including the Publix® and GEICO corporate offices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005057/en/

KB Home announces the grand opening of Meadows at Scott Lake Creek, its latest new-home community in Lakeland, Florida. (Photo: Business Wire)

KB Home announces the grand opening of Meadows at Scott Lake Creek, its latest new-home community in Lakeland, Florida. (Photo: Business Wire)

The homes at Meadows at Scott Lake Creek showcase popular design characteristics like gourmet kitchens overlooking expansive great rooms, master suites with walk-in closets, and large lofts. The community offers one- and two-story floor plans that feature up to six bedrooms and three baths, and range in size from approximately 1,500 to 3,000 square feet. Meadows at Scott Lake Creek also offers the KB Home Office, a dedicated room that homebuyers can personalize for the way they work. Residents will enjoy the community’s location being just minutes to shopping and dining in downtown Lakeland.

“Meadows at Scott Lake Creek’s commuter-friendly location is convenient to State Road 37 and Polk Parkway, and just a few miles to area employers and Lakeland Linder International Airport,” said Fred Wyborski, President of KB Home’s Orlando division. “Meadows at Scott Lake Creek provides home shoppers the opportunity to purchase a personalized, new KB home at a price that fits their budget.”

KB Home stands out from other homebuilders as the company gives homebuyers exceptional choice and control. KB Home starts by offering a wide variety of homes at an affordable price. From there, the builder gives buyers the ability to personalize their homes from homesites and floor plans to design features. The KB Home team works hand in hand with homeowners every step of the way so they have a real partner in the process.

Every KB home is designed to be ENERGY STAR® certified thanks to the quality construction techniques and materials utilized that ultimately deliver significant savings on utility bills compared to used homes. Additionally, all new KB homes are designed to deliver an enhanced indoor environment and include high performance ventilation systems, low- or zero-VOC products and other features guided by the Environmental Protection Agency’s (EPA) Indoor airPLUS standards.

The Meadows at Scott Lake Creek sales office and model home are open for private in-person tours by appointment, and walk-in visits are welcome. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the $240,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 42 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR® certified. In fact, we go beyond the EPA requirements by ensuring every ENERGY STAR certified KB home has been tested and verified by a third-party inspector to meet the EPA’s strict certification standards, which help to lower the cost of ownership and to make our new homes healthier and more comfortable than new ones without certification. We also work with our customers every step of the way, building strong personal relationships so they have a real partner in the homebuying process, and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

Cara Kane, KB Home

321-299-6844

[email protected]

KEYWORDS: California Florida United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Urban Planning REIT Landscape Interior Design Building Systems Architecture Other Construction & Property Residential Building & Real Estate

MEDIA:

Logo
Logo
Photo
Photo
KB Home announces the grand opening of Meadows at Scott Lake Creek, its latest new-home community in Lakeland, Florida. (Photo: Business Wire)

Krystal Biotech to Present at the Evercore ISI HealthCONx Conference

Krystal Biotech to Present at the Evercore ISI HealthCONx Conference

PITTSBURGH–(BUSINESS WIRE)–Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd Annual HealthCONx virtual conference taking place December 1-3, 2020.

Details for the webcast are as follows:

Evercore ISI 3rd Annual HealthCONx virtual conference

Presentation Date: Tuesday, December 1, 2020

Presentation Time: 1:50 p.m. ET

Webcast link: https://wsw.com/webcast/evercore11/krys/2405541

A webcast of the presentation will be available for 90 days and can be found on the Krystal Biotech website at: http://ir.krystalbio.com/events-and-presentations/events.

About Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel delivery platform to develop corrective, redosable therapies to address serious rare skin and lung diseases. For more information please visit http://www.krystalbio.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal’s product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of beremagene geperpavec (“B-VEC”), KB105, KB104, KB301 and KB407; the clinical utility of B-VEC, KB105, KB104, KB301 and KB407, and Krystal’s plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301 and KB407 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301 and KB407; plans to pursue research and development of other product candidates; the sufficiency of Krystal’s existing cash resources; the unanticipated impact of COVID-19 on Krystal’s business operations, pre-clinical activities and clinical trials; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301 and KB407, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s views as of any date subsequent to the date of this release.

Investors:

Whitney Ijem

[email protected]

Media:

Mary Coyle

TellMed Strategies

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Biotechnology General Health Pharmaceutical Health

MEDIA:

Logo
Logo

Dynatrace Named One of the Top 10 Highest-Rated Cloud Companies to Work For by Battery Ventures and Glassdoor

Dynatrace Named One of the Top 10 Highest-Rated Cloud Companies to Work For by Battery Ventures and Glassdoor

New report highlights the B2B cloud companies with the highest levels of employee satisfaction during the COVID-19 crisis

WALTHAM, Mass.–(BUSINESS WIRE)–
Software intelligence company Dynatrace (NYSE: DT), announced today it has been recognized as one of the top 10 Highest-Rated Cloud Computing Companies to Work For during the COVID-19 crisis, in a report released by Battery Ventures, with data provided by Glassdoor. The report is based on data collected during the first six months of the pandemic (March-August 2020) and includes B2B companies with the highest levels of employee satisfaction, according to employee feedback shared on Glassdoor, a worldwide leader on insights about jobs and companies. This distinction placed Dynatrace at number 10 on a list of 25 organizations.

Dynatrace received an overall rating of 4.6 from its employees, compared to the broader Glassdoor average of 3.5. Additionally, Dynatrace’s senior-leadership rating was 4.4, compared to the Glassdoor average of 3.2. Dynatrace also received a positive business-outlook rating, with 86% of its employees saying they believed the business would get better in the next six months, compared to the Glassdoor average of 51%. These results affirm the company’s commitment to establishing a work environment that fosters employees’ innovation while adjusting to support them during times of change.

“Cloud CEOs have had to stay unbelievably focused, resilient and nimble over the last eight months, working in conditions they likely never expected,” said Neeraj Agrawal, a Battery general partner who specializes in cloud investing. “The best CEOs are listening to employees and making tough decisions that will continue to move their companies forward. We’re heartened that so many of these B2B companies are surviving and even thriving during COVID-19, as they’re providing technologies to serve the new workforce, as well as solutions that are digitizing customer businesses faster than ever. Every company that made the list this year should view it as an honor to be included.”

This is the fourth year Battery Ventures has issued its ranking of the 25 Highest-Rated Cloud Computing Companies to Work For. This year’s ranking hinged on how companies are handling issues like remote workforces and the broader economic downturn and highlighted the global trend of businesses increasingly turning to the cloud to run critical technology systems and software. Separately, a recent Glassdoor economic research study showed that companies with high employee satisfaction often post stronger financial performance.

“We are honored to be recognized by Battery Ventures and Glassdoor as a top cloud company to work for. I’m especially proud that our placement on this list is a result of our employees’ positive sentiment during a particularly challenging time,” said John Van Siclen, CEO at Dynatrace. “I’ve witnessed the unrelenting commitment, positive attitude, and drive of our employees as they quickly adjusted to remote work to innovate for and serve our customers. I am gratified that this is also reflected in their attitudes toward the company.”

The full report including the complete list of the Battery Ventures Highest-Rated Cloud Companies to Work For can be found here.

About Dynatrace

Dynatrace provides software intelligence to simplify cloud complexity and accelerate digital transformation. With automatic and intelligent observability at scale, our all-in-one platform delivers precise answers about the performance of applications, the underlying infrastructure and the experience of all users to enable organizations to innovate faster, collaborate more efficiently, and deliver more value with dramatically less effort. That’s why many of the world’s largest enterprises trust Dynatrace® to modernize and automate cloud operations, release better software faster, and deliver unrivalled digital experiences.

Curious to see how you can simplify your cloud? Let us show you. Visit our trial page for a free 15-day Dynatrace trial.

To learn more about how Dynatrace can help your business, visit https://www.dynatrace.com, visit our blog and follow us on Twitter @dynatrace.

Hailey Melamut

March Communications

[email protected]

+1 617.960.9856

Tristan Webb

Spark Communications

[email protected]

+44 207.436.0420

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Data Management Technology Other Technology Mobile/Wireless Software Networks Internet

MEDIA:

Logo
Logo